Form 4: Bioxytran CEO David Platt Reports Acquisition of Common Stock
SEC Form 4 Filing
David Platt, CEO of Bioxytran, Inc., reports the acquisition of 439,595 shares of common stock at $0.104 per share, along with indirect ownership through NDPD Pharma, Inc.
Summary
- On March 27, 2024, David Platt, the CEO of Bioxytran, Inc. (BIXT), reported acquiring 439,595 shares of common stock.
- The acquisition price was $0.104 per share.
- Following the transaction, Platt's indirect beneficial ownership through NDPD Pharma, Inc. amounts to 20,133,018 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction. It is neutral in sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of shares by the CEO may signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: Acquisition of common stock by David Platt |
Keywords
Bioxytran, BIXT, David Platt, NDPD Pharma, common stock, beneficial ownership, Form 4, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.